Client Success: Incremental Borrowing Rate Analysis for Publicly Traded, Clinical Stage Biotech
![](https://rnaadvisors.com/wp-content/uploads/2019/07/The-Path-to-Commercialization-in-Life-Sciences-1024x615.jpg)
THE PROBLEM: A publicly traded clinical stage biotech company needed to understand the correct implied discount rate for a lease agreement in accordance with ASC 842 rules. THE SOLUTION: ASC 842 has specific rules relating to leases, including guidance on lease classification (operating versus financial) and how to discount a lessee’s lease payments to arrive […]
Client Success: Valuation Support for Licensing Transaction – Novel Cancer Therapy
![](https://rnaadvisors.com/wp-content/uploads/2016/08/iStock-910730068.jpg)
THE PROBLEM: Publicly traded late-stage therapeutics company negotiates with, and enters into, collaboration / license arrangement with a big pharma partner. THE SOLUTION: Forecasting, market research, modeling and transaction support combined with resultant collaboration agreement accounting analyses. “You were a great support for us, responsive and knowledgeable. Thank you!” CFO “You are my top go […]